People are hyped about PP405 but what about Veradermics phase 2! Research/Science 10/17/2025
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
View this post in the Community →
Similar Community Posts Join
5 / 47 resultscommunity VDPHL01 phase-2/3 results comparison
The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.
community 6 months before and after pics: VDPHL01 (oral minoxidil)
A user shared their positive experience with a clinical trial for a new oral medication, VDPHL01, which is a reformulated version of oral minoxidil taken at a high dose of 17mg daily, showing significant hair regrowth after six months. The user noted that this formulation is believed to be more effective and time-released, with fewer side effects compared to regular oral minoxidil.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
community I’m taking Veradermics VDPHL01 - AMA
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
community End of Hair loss ( AGA ) ? Since they produce it in china probably we don’t need to wait other 10 yrs😁
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
Related Research
6 / 11 resultsresearch A Decade of Autologous Micrografting Technology in Hair Restoration: A Review of Clinical Evidence and the Evolving Landscape of Regenerative Treatments
Autologous Micrografting Technology effectively improves hair growth and is a safe, promising option for hair restoration.
research Low-Dose Oral Minoxidil During Chemotherapy: A Review of the Mechanism and Current Evidence
Low-dose oral minoxidil might help with hair loss during chemotherapy, but more research is needed.
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
New treatments for hair loss show promise but need more testing for effectiveness and safety.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research Exploring novel management options for alopecia areata
JAK inhibitors can help treat alopecia areata but have risks and high costs.
research Universal Dermatology: Bridging Gaps in Skin Health
Inclusive dermatology aims to provide personalized skin care for all by addressing diverse needs and disparities.